TY - JOUR
T1 - Heterogeneity on long-term disability trajectories in patients with secondary progressive MS
T2 - a latent class analysis from Big MS Data network
AU - Signori, Alessio
AU - Lorscheider, Johannes
AU - Vukusic, Sandra
AU - Trojano, Maria
AU - Iaffaldano, Pietro
AU - Hillert, Jan
AU - Hyde, Robert
AU - Pellegrini, Fabio
AU - Magyari, Melinda
AU - Koch-Henriksen, Nils
AU - Sørensen, Per Soelberg
AU - Spelman, Tim
AU - van der Walt, Anneke
AU - Horakova, Dana
AU - Havrdova, Eva
AU - Girard, Marc
AU - Eichau, Sara
AU - Grand'Maison, Francois
AU - Gerlach, Oliver
AU - Terzi, Murat
AU - Ozakbas, Serkan
AU - Skibina, Olga
AU - Van Pesch, Vincent
AU - Sa, Maria Jose
AU - Prevost, Julie
AU - Alroughani, Raed
AU - McCombe, Pamela A
AU - Gouider, Riadh
AU - Mrabet, Saloua
AU - Castillo-Trivino, Tamara
AU - Zhu, Chao
AU - de Gans, Koen
AU - Sánchez-Menoyo, José Luis
AU - Yamout, Bassem
AU - Khoury, Samia
AU - Sormani, Maria Pia
AU - Kalincik, Tomas
AU - Butzkueven, Helmut
AU - Big MS Data Network
N1 - © Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.
PY - 2023/1
Y1 - 2023/1
N2 - BACKGROUND: Over the decades, several natural history studies on patients with primary (PPMS) or secondary progressive multiple sclerosis (SPMS) were reported from international registries. In PPMS, a consistent heterogeneity on long-term disability trajectories was demonstrated. The aim of this study was to identify subgroups of patients with SPMS with similar longitudinal trajectories of disability over time.METHODS: All patients with MS collected within Big MS registries who received an SPMS diagnosis from physicians (cohort 1) or satisfied the Lorscheider criteria (cohort 2) were considered. Longitudinal Expanded Disability Status Scale (EDSS) scores were modelled by a latent class growth analysis (LCGA), using a non-linear function of time from the first EDSS visit in the range 3-4.RESULTS: A total of 3613 patients with SPMS were included in the cohort 1. LCGA detected three different subgroups of patients with a mild (n=1297; 35.9%), a moderate (n=1936; 53.6%) and a severe (n=380; 10.5%) disability trajectory. Median time to EDSS 6 was 12.1, 5.0 and 1.7 years, for the three groups, respectively; the probability to reach EDSS 6 at 8 years was 14.4%, 78.4% and 98.3%, respectively. Similar results were found among 7613 patients satisfying the Lorscheider criteria.CONCLUSIONS: Contrary to previous interpretations, patients with SPMS progress at greatly different rates. Our identification of distinct trajectories can guide better patient selection in future phase 3 SPMS clinical trials. Additionally, distinct trajectories could reflect heterogeneous pathological mechanisms of progression.
AB - BACKGROUND: Over the decades, several natural history studies on patients with primary (PPMS) or secondary progressive multiple sclerosis (SPMS) were reported from international registries. In PPMS, a consistent heterogeneity on long-term disability trajectories was demonstrated. The aim of this study was to identify subgroups of patients with SPMS with similar longitudinal trajectories of disability over time.METHODS: All patients with MS collected within Big MS registries who received an SPMS diagnosis from physicians (cohort 1) or satisfied the Lorscheider criteria (cohort 2) were considered. Longitudinal Expanded Disability Status Scale (EDSS) scores were modelled by a latent class growth analysis (LCGA), using a non-linear function of time from the first EDSS visit in the range 3-4.RESULTS: A total of 3613 patients with SPMS were included in the cohort 1. LCGA detected three different subgroups of patients with a mild (n=1297; 35.9%), a moderate (n=1936; 53.6%) and a severe (n=380; 10.5%) disability trajectory. Median time to EDSS 6 was 12.1, 5.0 and 1.7 years, for the three groups, respectively; the probability to reach EDSS 6 at 8 years was 14.4%, 78.4% and 98.3%, respectively. Similar results were found among 7613 patients satisfying the Lorscheider criteria.CONCLUSIONS: Contrary to previous interpretations, patients with SPMS progress at greatly different rates. Our identification of distinct trajectories can guide better patient selection in future phase 3 SPMS clinical trials. Additionally, distinct trajectories could reflect heterogeneous pathological mechanisms of progression.
KW - Disabled Persons
KW - Disease Progression
KW - Humans
KW - Latent Class Analysis
KW - Multiple Sclerosis, Chronic Progressive/drug therapy
KW - Multiple Sclerosis/drug therapy
KW - Registries
UR - http://www.scopus.com/inward/record.url?scp=85144239897&partnerID=8YFLogxK
U2 - 10.1136/jnnp-2022-329987
DO - 10.1136/jnnp-2022-329987
M3 - Journal article
C2 - 36171104
SN - 0022-3050
VL - 94
SP - 23
EP - 30
JO - Journal of neurology, neurosurgery, and psychiatry
JF - Journal of neurology, neurosurgery, and psychiatry
IS - 1
ER -